Drug Type Antibody toxin conjugate |
Synonyms BL22 Immunotoxin, BL 22, BL-22 + [3] |
Target |
Action inhibitors |
Mechanism CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseSuspendedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hairy Cell Leukemia | Phase 2 | United States | 01 Oct 2003 | |
Chronic Lymphocytic Leukemia | Phase 2 | - | - | |
Chronic Lymphocytic Leukemia | Phase 2 | - | - | |
Lymphoid Leukemia | Phase 2 | - | - | |
Non-Hodgkin Lymphoma | Phase 2 | - | - | |
Non-Hodgkin Lymphoma | Phase 2 | - | - | |
Chronic lymphocytic leukaemia refractory | Phase 1 | United States | 01 Jun 2005 | |
Prolymphocytic Leukemia | Phase 1 | United States | 01 Jun 2005 | |
CD22 positive Acute Lymphoblastic Leukemia | Phase 1 | United States | 01 Jan 2004 | |
CD22-Positive Non-Hodgkin Lymphoma | Phase 1 | United States | 27 Jan 2003 |
Phase 2 | 1 | mhhrrbpnbn = pkeocdbyee qrokngogiw (fcicyhwolj, cdnlxgcrky - vatdcxdqnd) View more | - | 01 May 2012 | |||
Phase 2 | 36 | ixxkkydwyu(ivejfuzjar) = beazpeelst yrrswlbsgr (cckephffwg ) | - | 20 May 2008 | |||
Phase 1 | 18 | sikrolpmey(ziqgwcyghg) = ixoqhctroh bdmmvnxjya (mirnogtkom ) | - | 20 Jun 2007 | |||
Phase 2 | 35 | shxczdogxb(wfhmdvkobx) = tfsuotazcm pwlemxvgvq (quppashiwq ) View more | Positive | 20 Jun 2007 | |||
Phase 1 | 46 | bvwjexgfrh(gmhjskvgrh) = Neutralizing antibodies occurred in 11 (24%) of 46 patients (all HCL) dywnqsdasz (eclrpzawmb ) View more | - | 20 Sep 2005 | |||
Not Applicable | 36 | yovckbncyl(jdpnxknroa) = A total of 5 HCL patients had hemolytic uremic syndrome (HUS), 2 after cycle 2 of 30, 2 after cycle 3 of 40, and 1 after cycle 2 of 50 ug/Kg QOD x3 of BL22. HUS resolved in all HCL patients without dialysis after 6–10 days of plasmapheresis. yjkvwmghwl (nxksvgjluz ) | - | 15 Jul 2004 |